<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119362</url>
  </required_header>
  <id_info>
    <org_study_id>PARAGON</org_study_id>
    <secondary_id>AIO-LQ-0214</secondary_id>
    <nct_id>NCT04119362</nct_id>
  </id_info>
  <brief_title>PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer</brief_title>
  <acronym>PARAGON</acronym>
  <official_title>PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to the generally poor prognosis, with no chance of long-term survival, health related&#xD;
      quality of life is a very important objective in the treatment of patients with pancreatic&#xD;
      cancer. The non-interventional, prospective, multicentre PARAGON study is desinged to&#xD;
      evaluate the health-related quality of life in patients with metastatic pancreatic cancer, by&#xD;
      analyzing the course of QoL throughout all applied therapy lines for patients with pancreatic&#xD;
      adenocarcinoma, measured according to EORTC scoring manual and patient reported outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is often diagnosed at an advanced stage, because most of the patients have&#xD;
      no symptoms until the cancer metastasized. In the majority of study cases pancreatic cancer&#xD;
      research focuses on therapy outcomes and prognosis. With poor prognosis and no chance of&#xD;
      long-term survival, quality of life becomes a very significant purpose of pancreatic cancer&#xD;
      care.&#xD;
&#xD;
      The PARAGON study is designed to see a bigger picture by acquiring data on quality of life&#xD;
      (QoL) and further outcome of patients with localized, locally advanced and metastatic&#xD;
      pancreatic cancer and moreover to establish a sample collection for future biomarker&#xD;
      analysis.&#xD;
&#xD;
      The multicenter, prospective, permanent, register study PARAGON collects outcome data,&#xD;
      patient reported outcomes (PRO), and tumor tissues of pancreatic cancer patients of both&#xD;
      sexes and ages over 18 at approx. 80 German study sites. Patients diagnosed with pancreatic&#xD;
      adenocarcinoma planned for (or recently started with) neoadjuvant, adjuvant or 1st line&#xD;
      therapy can be included into the study.&#xD;
&#xD;
      The data assessment includes data on demography, basic parameters, anamnesis, comorbidities,&#xD;
      therapies, outcome and survival data as well as patient reported outcome in QoL at baseline&#xD;
      and every 8 weeks.&#xD;
&#xD;
      PARAGON's first objective is to determine the course of QoL throughout all applied therapy&#xD;
      lines for patients with pancreatic adenocarcinoma, measured according to EORTC scoring manual&#xD;
      and patient reported outcome. Secondary outcome measurements are e.g. progression-free,&#xD;
      disease-free and overall survival according to treatment line.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">January 2029</completion_date>
  <primary_completion_date type="Anticipated">January 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>The course of Quality of Life (QoL) throughout the entire course of therapy for patients with pancreatic adenocarcinoma</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>EORTC-QLQC30 according to EORTC scoring manual</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Other patient reported outcome (PRO)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Physical performance status patient questionnaire according to ECOG criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression- free survival (PFS)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>As for the main objective, there is no formal secondary endpoint in a registry study. Therfore, in this section we will explain the main data to be collected and the main outcome measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>As for the main objective, there is no formal secondary endpoint in a registry study. Therfore, in this section we will explain the main data to be collected and the main outcome measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>As for the main objective, there is no formal secondary endpoint in a registry study. Therfore, in this section we will explain the main data to be collected and the main outcome measures.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Patients with pancreatic adenocarcinoma</arm_group_label>
    <description>Patients with metastatic pancreatic cancer receiving will be asked to fill in an EORTC QLQ-C30 questionnaire and additional questionnaires on worries about quality of life impairments and physical constitiution every 8 weeks, over the entire course of treatment, starting with neo-/adjuvant or 1st line therapy follow. There is no restriction on type of therapy. No further intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of live questionnaires</intervention_name>
    <description>EORTC-Q30 questionnaire, additonal questionnaire on worries about quality of life impairments and on physical condition every 8 weeks. No additional visits will be carried out for questionnaires. Questionnaires will be handed out to patients during routine visits.</description>
    <arm_group_label>Patients with pancreatic adenocarcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optional translational project</intervention_name>
    <description>Collection of archival tumor material for future translational projects. No biopsy will be performed in the context of this registry. Only tumor samples obtained in the context of standard of care and after explicit informed context will be used.</description>
    <arm_group_label>Patients with pancreatic adenocarcinoma</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Formalin Fixed and Paraffin Embedded Tumor Tissue (FFPE)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pancreatic adenocarcinoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent and signed data protection form before any study specific&#xD;
             intervention, including screening, will be done&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed pancreatic adenocarcinoma&#xD;
&#xD;
          -  Systemic neoadjuvant, adjuvant, 1st line systemic therapy is planned or recently&#xD;
             started (within last 14 days)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unable to consent because they do not understand the nature,&#xD;
             significance and implications of the study&#xD;
&#xD;
          -  Patients who are unable to understand or fill out the QoL survey&#xD;
&#xD;
          -  Patients in 2nd or further treatment lines that have not been documented for 1st line&#xD;
             therapy within the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Nordwest gGmbH Institut für Klinisch-Onkologische Forschung</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thorsten Goetze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Nordwest gGmbH Institut für Klinisch-Onkologische Forschung</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralf Hofheinz, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salah-Eddin Al-Batran, MD</last_name>
    <phone>+4969-7601-3788</phone>
    <email>albatran@ikf-khnw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bianca Zäpf</last_name>
    <phone>+4969-7601-4636</phone>
    <email>zaepf.bianca@ikf-khnw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HELIOS Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Pink, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical Cancer Research Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten O Götze, Dr.</last_name>
      <phone>+49697601</phone>
      <phone_ext>4187</phone_ext>
      <email>goetze.thorsten@khnw.de</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Steinmetz</last_name>
      <phone>+49697601</phone>
      <phone_ext>4487</phone_ext>
      <email>steinmetz.kristina@khnw.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Herne</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Strumberg, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BAG Innere Medizin - Hämatologie - Onkologie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catarina Stosiek</last_name>
      <phone>+49941-2060304-32</phone>
    </contact>
    <contact_backup>
      <last_name>Anna Diepold</last_name>
      <phone>+49941-2060304-33</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Elblandklinikum Riesa</name>
      <address>
        <city>Riesa</city>
        <zip>01589</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Schubert, Prof.</last_name>
      <phone>+49352575 5697</phone>
      <email>Joerg.Schubert@elblandkliniken.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreas</keyword>
  <keyword>quality of life</keyword>
  <keyword>PRO</keyword>
  <keyword>Pancreatic Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

